Description
Latin name
Omnitus
Pharmacological action
Antitussive, has an expectorant, moderate bronchodilating andanti-inflammatory effect.
Butamyrate citrate is neither chemically nor pharmacologically related to opium alkaloids and has a direct effect on the cough center, improves spirometry and blood oxygenation.
Pharmacokinetics
Absorption – High. After ingestion of a syrup in a dose containing 150 mg of butyrate citrate, the maximum plasma concentration of the main metabolite (2-phenylbutyric acid) is observed after 1.5 hours and amounts to 6.4 μg / ml, when taking a tablet with a modified release (50 mg), respectively, – 9 h and 1.4 μg / ml. The half-life for syrup is 6 hours, for tablets – 13 hours. There is no cumulative effect. Butamyrate citrate is rapidly hydrolyzed in plasma to 2-phenylbutyric acid and diethylaminoethoxyethanol. Both of these metabolites, which also have an antitussive effect, largely bind to plasma proteins, which explains their prolonged presence in plasma. Subsequently, the main metabolite of 2-phenylbutyric acid is oxidized to 14C-p-hydroxy-2-phenylbutyric acid. All three metabolites are excreted by the kidneys, and acidic metabolites are mainly associated with glucuronic acid.
Indications
Dry cough of any etiology (for colds, flu, whooping cough and other conditions) to suppress cough in the preoperative and postoperative period, during surgery, bronchoscopy.
Contraindications
hypersensitivity
pregnancy
lactation
children under 18 years of age
Use during pregnancy and lactation
The use of the drug in the form of syrup during pregnancy is contraindicated, in the form of tablets in the first trimester of pregnancy.
If you need to use the drug during lactation, you should decide whether to stop breastfeeding.
Composition
1 tablet with a modified release film-coated
50 mg contains:
Active ingredient
Butyramide citrate 50 mg
Excipients
mg lactose 230 mg lactose , 0 mg, talc – 10.0 mg, magnesium stearate – 12.0 mg, silicon dioxide colloidal, anhydrous – 6.0 mg, povidone – 1.5 mg,
Shell composition
hypromellose – 5.305 mg, talc – 4.950 mg ethyl cellulose – 3.183 mg, macrogol – 1.273 mg, titanium dioxide – 1.061 mg, crimson dye [Ponceau 4R] [E 124] – 2.122 g brown varnish (sunset yellow dye [E110], a colorant azorubin [E122], black dye [E151]) – 0.106 mg.
Dosage and Administration
Inside. Tablets are taken before meals, without chewing.
Tablets, 50 mg
Adults – 2 tablets. 2-3 times a day.
Side effects
From the digestive system: nausea, diarrhea.
Other: exanthema, dizziness, allergic reactions.
Overdose
Symptoms: nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure.
Treatment: inside – activated charcoal, saline laxatives, if necessary – symptomatic therapy.
Storage Conditions
At 15 ° C to 25 ° C.
Term hodnosty
2 years
active substance
butamirata
Terms leave through pharmacies
without prescription
Dosage form
tablet prolong.
